JP2008518974A5 - - Google Patents

Download PDF

Info

Publication number
JP2008518974A5
JP2008518974A5 JP2007539372A JP2007539372A JP2008518974A5 JP 2008518974 A5 JP2008518974 A5 JP 2008518974A5 JP 2007539372 A JP2007539372 A JP 2007539372A JP 2007539372 A JP2007539372 A JP 2007539372A JP 2008518974 A5 JP2008518974 A5 JP 2008518974A5
Authority
JP
Japan
Prior art keywords
composition
long chain
nkt cell
composition according
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007539372A
Other languages
English (en)
Japanese (ja)
Other versions
JP4948418B2 (ja
JP2008518974A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/040182 external-priority patent/WO2006060117A2/en
Publication of JP2008518974A publication Critical patent/JP2008518974A/ja
Publication of JP2008518974A5 publication Critical patent/JP2008518974A5/ja
Application granted granted Critical
Publication of JP4948418B2 publication Critical patent/JP4948418B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007539372A 2004-11-02 2005-11-02 Ｎｋｔ細胞を抑制するための方法 Expired - Fee Related JP4948418B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62456804P 2004-11-02 2004-11-02
US60/624,568 2004-11-02
US70654805P 2005-08-08 2005-08-08
US60/706,548 2005-08-08
PCT/US2005/040182 WO2006060117A2 (en) 2004-11-02 2005-11-02 Methods for inhibition of nkt cells

Publications (3)

Publication Number Publication Date
JP2008518974A JP2008518974A (ja) 2008-06-05
JP2008518974A5 true JP2008518974A5 (enExample) 2008-11-27
JP4948418B2 JP4948418B2 (ja) 2012-06-06

Family

ID=36565493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007539372A Expired - Fee Related JP4948418B2 (ja) 2004-11-02 2005-11-02 Ｎｋｔ細胞を抑制するための方法

Country Status (11)

Country Link
US (2) US7682614B2 (enExample)
EP (1) EP1812015B1 (enExample)
JP (1) JP4948418B2 (enExample)
CN (1) CN101031307B (enExample)
AT (1) ATE539757T1 (enExample)
AU (1) AU2005310247A1 (enExample)
CA (1) CA2584971C (enExample)
DK (1) DK1812015T3 (enExample)
ES (1) ES2378076T3 (enExample)
PT (1) PT1812015E (enExample)
WO (1) WO2006060117A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254396A1 (en) 2001-03-26 2002-10-08 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
EP2575824A4 (en) * 2010-05-24 2014-02-19 Childrens Medical Center METHOD FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
DK2643346T3 (en) * 2010-11-25 2018-10-29 Imnate Sarl MODULATION OF ANTIGEN IMMUNOGENICITY BY ADDITION OF EPITOPES RECOGNIZED BY NKT CELLS
EP2731617A4 (en) 2011-07-12 2015-07-01 Brigham & Womens Hospital LIPID-BASED PSA COMPOSITIONS, METHOD FOR THEIR INSULATION AND USE METHOD THEREFOR
CN103945867B (zh) * 2011-10-27 2018-01-02 Nkt治疗公司 针对iNKT的人类化抗体
EP2906576B1 (en) 2012-10-12 2019-09-11 The Brigham and Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CA2910766C (en) 2013-04-30 2020-12-15 Otitopic Inc. Dry powder formulations and methods of use
JP6743051B2 (ja) 2015-01-27 2020-08-19 ラヴァ・セラピューティクス・ベー・フェー Ｃｄ１ｄを標的とする単一ドメイン抗体
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHOD FOR USE
WO2019059953A2 (en) 2017-09-22 2019-03-28 Otitopic Inc. DRY POWDER COMPOSITIONS CONTAINING MAGNESIUM STEARATE
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
EP3853255A1 (en) 2018-09-19 2021-07-28 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
IL305579A (en) 2021-03-01 2023-10-01 Deciduous Therapeutics Inc Compounds for activating invariant natural killer T cells and methods for use in eliminating inflammatory senescent cells
EP4480486A1 (en) * 2022-02-14 2024-12-25 Riken Nkt cell ligand-containing liposome composition

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US7063844B2 (en) * 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US5679347A (en) * 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
DE69433115T2 (de) 1993-06-21 2004-04-01 Brigham And Women's Hospital, Boston Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
ATE421881T1 (de) * 1997-04-10 2009-02-15 Kyowa Hakko Kirin Co Ltd Nkt-zellenaktivatoren, die alpha-glycosylceramide enthalten
EP1011719A1 (en) * 1997-09-12 2000-06-28 Brigham & Women's Hospital Synthetic antigens for cd1-restricted immune responses
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
AU4837499A (en) 1998-07-09 2000-02-01 Brian J. Nickoloff Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
US20010051156A1 (en) * 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
WO2001094949A2 (en) 2000-06-05 2001-12-13 The Brigham And Women's Hospital, Inc. Soluble cd1 compositions and uses thereof
CN1444648A (zh) * 2000-06-06 2003-09-24 麒麟麦酒株式会社 扩增自然杀伤t细胞的方法
PT1297017E (pt) * 2000-06-19 2012-09-04 Gen Hospital Corp Composições e métodos de anticorpos monoclonais e policlonais específicos para subpopulações de célula t
US20020115624A1 (en) * 2000-06-22 2002-08-22 Behar Samuel M. Alpha gylcosylceramides for treating bacterial and fungal infections
WO2002016825A1 (fr) * 2000-08-18 2002-02-28 Mitsubishi Denki Kabushiki Kaisha Douille et transformateur pour lampe et procede de fabrication d'un transformateur pour lampe
DE10046658A1 (de) 2000-09-20 2002-04-04 Bosch Gmbh Robert Induktiver Übertrager und ein Verfahren zu dessen Herstellung
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
IL140537A0 (en) * 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
AU2002254396A1 (en) * 2001-03-26 2002-10-08 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US6662434B2 (en) * 2001-04-03 2003-12-16 General Electric Company Method and apparatus for magnetizing a permanent magnet
US8178098B2 (en) * 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
CA2444429A1 (en) * 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20020171538A1 (en) * 2001-05-15 2002-11-21 Kuo-Hsin Su Vehicle motion detector and control device arrangement
US20020171557A1 (en) * 2001-05-18 2002-11-21 Wegener William E. Security electronic system
JP2005500336A (ja) * 2001-07-25 2005-01-06 ニューヨーク・ユニバーシティ 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用
AU2003234443A1 (en) 2002-05-01 2003-11-17 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
US7273852B2 (en) * 2002-06-13 2007-09-25 The Research Foundation Of The City University Of New York Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
DE60239566D1 (de) 2002-06-14 2011-05-05 Brigham And Women S Hospital Boston Verfahren zur behandlung und prävention von kolitis, an der il-13 und nk-t zellen beteiligt sind
US7368142B2 (en) * 2002-08-01 2008-05-06 Renew Life Formulas, Inc. Natural sweetener
JP2006511462A (ja) 2002-08-27 2006-04-06 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 上皮組織損傷又は脱毛症の予防又は治療
AU2003277021A1 (en) 2002-09-27 2004-04-19 Biomira, Inc. Glycosylceramide analogues
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040171522A1 (en) * 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040235162A1 (en) * 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
AU2003225891A1 (en) 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
WO2004084874A2 (en) 2003-03-24 2004-10-07 Brigham And Women's Hospital, Inc. Mtp inhibitors for inhibiting inflammation
EP1653977A2 (en) 2003-07-17 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of disorders associated with natural killer t cells
AU2005251589B2 (en) * 2004-06-11 2011-01-06 Riken Drug having regulatory cell ligand contained in liposome

Similar Documents

Publication Publication Date Title
JP2008518974A5 (enExample)
Chen et al. Berberine protects against neuronal damage via suppression of glia-mediated inflammation in traumatic brain injury
Luo et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator‐activated receptor‐γ agonist rosiglitazone
Casali et al. Omega-3 fatty acids augment the actions of nuclear receptor agonists in a mouse model of Alzheimer's disease
Ohnishi et al. HMGB1 inhibitor glycyrrhizin attenuates intracerebral hemorrhage-induced injury in rats
US10639301B2 (en) Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug
Kaur et al. Hypoxia-ischemia and retinal ganglion cell damage
JP2016525140A5 (enExample)
MX395136B (es) Composiciones farmaceuticas y metodos de administracion relacionados.
Tang et al. Conjugated linoleic acid attenuates 2, 4-dinitrofluorobenzene-induced atopic dermatitis in mice through dual inhibition of COX-2/5-LOX and TLR4/NF-κB signaling
HRP20230809T1 (hr) Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
JP2010518029A5 (enExample)
JP6609320B2 (ja) ノカルダミンの新規金属錯体および医薬組成物におけるそれらの使用
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
Padmanaban et al. Curcumin may defy medicinal chemists
Tollesson et al. Malassezia furfur in infantile seborrheic dermatitis
WO2022256291A1 (en) Hydrogel devices for drug delivery to the ear
Eberting Irritant contact dermatitis: mechanisms to repair
Beray-Berthat et al. Long-term histological and behavioural characterisation of a collagenase-induced model of intracerebral haemorrhage in rats
Nowak-Machen et al. Lysophosphatidic acid generation by pulmonary NKT cell ENPP-2/autotaxin exacerbates hyperoxic lung injury
FR3130140B1 (fr) Agent de traitement capillaire avec effet de soin amélioré
Yanık et al. Current neuroprotective agents in stroke
Strosznajder et al. Effects of p53 inhibitor on survival and death of cells subjected to oxidative stress
BRPI0409456A (pt) métodos para o tratamento e/ou prevenção de doenças ligadas ao acúmulo de triglicerìdeos em tecidos e sangue, de doenças ligadas a uma falta de equilìbrio de colesterol em prejuìzo de colesterol hdl em tecidos e sangue, métodos de tratamento para diminuir os nìveis no sangue de triglicerìdeos, para equilibrar o nìvel no sangue e/ou tecidos de colesterol total em favor de colesterol hdl, para abaixar os nìveis de triglicerìdeo no fìgado, método para o tratamento ou prevenção de uma condição obesa, método de tratamento para a redução ou inibição do ganho de gordura corporal, método para aliviar a resistência ou restaurar a sensibilidade a insulina, uso de ácido beta-aminoisobutìrico, derivado, prodroga, metabólito ou complexo do mesmo, composição farmacêutica, composição nutricional, e, método para produzir redução de massa de gordura
Fredriksson et al. Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration